![](\"https:\/\/mms.businesswire.com\/media\/20260602949700\/en\/2820484\/5\/Pierre_Chevineau_Board_%28003%29.jpg\")
<\/a><\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260602949700\/en\/2820453\/4\/FineHeart.jpg\")
<\/a><\/a>\nThis appointment comes at a strategic stage in FineHeart\u2019s development, as the company simultaneously accelerates its clinical and industrial programs for FlowMaker\u00ae and prepares the next phases of its international expansion. With a recognized profile within the international medtech ecosystem, extensive cardiovascular sector expertise, and a strong track record in supporting innovative companies through structuring, acceleration, and scale-up phases, Pierre Chauvineau\u2019s arrival further strengthens FineHeart\u2019s experienced governance.<\/p>
\nJean-Luc Boulnois, Chairman of FineHeart\u2019s Board of Directors, commented<\/b>: \u201cWe are delighted to welcome Pierre Chauvineau to our Board of Directors, which is fully committed to supporting FineHeart\u2019s development strategy. His profile complements a highly engaged governance team dedicated to advancing FineHeart\u2019s ambitions. His international medtech experience, deep understanding of the cardiovascular sector, and expertise in international market access challenges will be valuable assets in supporting the company\u2019s scale-up<\/i>.\u201d<\/p>
\nArnaud Mascarell, Chief Executive Officer and co-founder of FineHeart, added<\/b>: \u201cPierre\u2019s arrival marks an important step in supporting our clinical, industrial, and international ambitions. With FlowMaker\u00ae at the core of our strategy, we are developing highly differentiated proprietary technology building blocks<\/i> \u2013 including transcutaneous wireless energy and data transfer, implantable electronics, intelligent physiological control, and associated digital technologies \u2013 whose potential could extend to other applications in the field of active implantable medical devices. Pierre\u2019s experience in bringing innovative medical technologies to market will be particularly valuable for FineHeart<\/i>.\u201d<\/p>
\nPierre Chauvineau concluded<\/b>: \u201cI am impressed by the quality of the team, the strategic vision driven by FineHeart\u2019s management, and the complementarity of the existing Board of Directors. FlowMaker\u00ae embodies an exceptional technological and medical ambition aimed at addressing a major clinical need that remains largely unmet. I am delighted to contribute to its success alongside the management team and the Board<\/i>.\u201d<\/p>
\nPierre Chauvineau\u2019s career<\/b><\/p>
\nWith more than 35 years of experience gained within major corporations and high-growth innovative companies, Pierre\u2019s career combines operational expertise, strategic vision, leadership, and support for innovative companies in medical technologies and value creation within highly regulated environments.<\/p>
\nThroughout his career, Pierre has held senior executive leadership roles at Boston Scientific, Medtronic, and Cameron Health, leading large-scale international operations, including one of Boston Scientific's largest European business units, and contributing to the global launch of innovative medical technologies.<\/p>
\nPierre also has extensive governance experience and a strong track record in supporting rapidly growing innovative companies. He chairs several boards of directors in the medtech and digital health sectors, including Sequana Medical, and actively collaborates with executives, investors, and European innovation programs.<\/p>
\nAbout FineHeart FineHeart<\/a><\/b><\/p> \nMedia Relations<\/b> An international medtech executive to support the company\u2019s scale-upBORDEAUX, France–(BUSINESS WIRE)–FineHeart, a French clinical-stage medtech company developing FlowMaker\u00ae, a breakthrough therapy for the treatment of advanced heart failure, announ…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-14579","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14579"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14579\/revisions"}],"predecessor-version":[{"id":14580,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14579\/revisions\/14580"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}